OncoMatch/Clinical Trials/NCT06228482
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Is NCT06228482 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. for metastatic nonsmall cell lung cancer.
Treatment: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ITGB6 overexpression (SUVmax >2-fold above normal bone, brain, lung or liver on [68Ga]Ga DOTA-5G PET/CT) (SUVmax >2-fold above normal bone, brain, lung or liver)
The presence of at least one measurable disease by [68Ga]Ga DOTA-5G PET/CT (SUVmax>2-fold above normal bone, brain, lung or liver and identified on standard of care diagnostic imaging)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: FDA approved systemic regimen — metastatic
documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1000 cells/mm3; platelet count ≥ 100,000/mm3; hemoglobin ≥ 8 g/dl
Kidney function
creatinine ≤ 2 times uln
Liver function
ast, alt, alkaline phosphatase ≤ 5 times upper limit of normal (uln); total bilirubin ≤ 2 times uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify